Testing BI 3032950 for People With Ulcerative Colitis
Tests BI 3032950, given by infusion then injection, in adults with ulcerative colitis.
Plain-language title generated from the registry record
Registry title: A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis
Key facts
- Where
- Cedar Park, Charlotte, Colorado Springs, Gurnee, Houston, Kansas City, Kissimmee, Lakewood Rch, Miami, New York, Scottsdale, Seattle, and Tacoma, United StatesSee the 14 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06636656, who can take part
Where in United States
- Texas Digestive Disease ConsultantsCedar Park, United StatesTaking people
- Atrium Health Gastroenterology and HepatologyCharlotte, United StatesTaking people
- Peak Gastroenterology AssociatesColorado Springs, United StatesTaking people
- Illinois Gastroenterology Group - GurneeGurnee, United StatesTaking people
- Baylor College of MedicineHouston, United StatesTaking people
- University of Kansas Medical CenterKansas City, United StatesTaking people
- Primary Care of OsceolaKissimmee, United StatesNot yet recruiting
- Florida Research InstituteLakewood Rch, United StatesTaking people
- Reliant Medical ResearchMiami, United StatesTaking people
- University of MiamiMiami, United StatesTaking people
- Columbia University Medical CenterNew York, United StatesNot yet recruiting
- One of a Kind Clinical Research CenterScottsdale, United StatesNot yet recruiting
- University of WashingtonSeattle, United StatesNot yet recruiting
- Digestive Health SpecialistsTacoma, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Boehringer Ingelheim
- Trial code
- NCT06636656EU 2023-509544-10-00
- Record updated
- 21 August 2026
- Original description
Adults between 18 and 80 years of age with ulcerative colitis can participate in this study. This is a study for people for whom previous treatment was not successful or who stopped previous treatment. The purpose of this study is to find out whether BI 3032950 helps people with ulcerative colitis.Read full original descriptionShow less
Phase IIa, Sequential Cohort, Open-label, Multi-center Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of Intravenous Induction and Subcutaneous Maintenance Treatment With BI 3032950 in Patients With Moderate to Severe Ulcerative Colitis
Adults between 18 and 80 years of age with ulcerative colitis can participate in this study. This is a study for people for whom previous treatment was not successful or who stopped previous treatment. The purpose of this study is to find out whether BI 3032950 helps people with ulcerative colitis.
This study has 2 parts. In Part A, participants get BI 3032950 as an infusion into a vein every 4 weeks. After 12 weeks, doctors check whether the signs and symptoms of ulcerative colitis have improved. Before the results of this assessment are available, participants move on to Part B and get BI 3032950 as an injection under the skin. Participants whose results show clinical response after 12 weeks can continue treatment with BI 3032950. They get BI 3032950 injections under the skin every 4 weeks for up to 2 years.
Participants visit their doctors every 4 weeks. During these visits, the doctors check the signs and symptoms of ulcerative colitis. This includes taking blood and stool samples. Doctors also do endoscopies. This is a procedure that uses a tube with a camera to look inside the body.
The doctors also regularly check participants' health and take note of any unwanted effects.
Inclusion: Female and male participants aged 18 to 80 years (inclusive) at the time of informed consent,; Diagnosis of ulcerative colitis (UC) ≥3 months prior to screening by clinical and endoscopic evidence corroborated by a histopathology report,; Inadequate response, loss of response, or intolerance to treatment with biologic/targeted therapy or termination of treatment with biologic/targeted therapy for any other reason,; Female participants of childbearing potential must be ready and able to use highly effective methods of birth control and male participants are required to use condoms,; Further inclusion criteria apply.
Exclusion: Previous surgery or anticipated surgical intervention for UC (trial participants with previous colonic surgery may be allowed based on investigator's judgement after discussion with the sponsor),; Any current or prior abscesses, unless they have been drained and treated at least 6 weeks prior to first trial drug administration and are not anticipated to require surgery,; Diagnosis of indeterminate colitis, ischemic colitis, radiation colitis, diverticular disease associated with colitis, microscopic colitis, or Crohn's disease (CD),; Findings suggestive of CD (e.g. fistulae, granulomas on biopsy),; Evidence of colonic moderate/severe mucosal dysplasia or colonic adenomas, unless properly removed,; Gastrointestinal neoplasia, primary sclerosing cholangitis, or known colonic stricture,; Evidence of fulminant colitis or toxic megacolon at screening,; Current ileal-pouch anal anastomosis, ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine,; Further exclusion criteria apply.